Letter: which patients with hepatitis B virus‐related hepatocellular carcinoma should receive nucleos(t)ide analogue therapy?

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2036|44|8|908-910

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.44, Iss.8, 2016-10, pp. : 908-910

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: A population‐based cohort study

By  

CANCER, Vol. 121, Iss. 9, 2015-05 ,pp. : 1446-1455

John Wiley & Sons Inc

Access to resources Recommend Favorite

Utility of Prediction Scores for Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Treated with Nucleos(t)ide Analogues

By  

Oncology, Vol. 90, Iss. 4, 2016-03 ,pp. : 199-208

Karger

Access to resources Recommend Favorite

Systematic review: cessation of long‐term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen‐negative chronic hepatitis B

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 3, 2015-08 ,pp. : 243-257

John Wiley & Sons Inc

Access to resources Recommend Favorite

Reduced risk of relapse after long‐term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 9, 2015-05 ,pp. : 867-876

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: pre‐ and post‐operative anti‐viral therapy is important for patients with hepatitis B virus‐related hepatocellular carcinoma

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 41, Iss. 8, 2015-04 ,pp. : 789-790

John Wiley & Sons Inc

Access to resources Recommend Favorite